Objective: To investigate the effect of intravesical onabotulinumtoxinA (Botox) injection on female sexual function in women with overactive bladder (OAB) and to evaluate its relationship with OAB symptoms. Material and Methods: Data from 56 patients with idiopathic OAB and who were resistant to medical therapy between January 2018 and July 2019 were evaluated. The patients were evaluated with an overactive bladder symptom score (OABSS) and female sexual function index (FSFI) before and after 100 IU Botox treatment. The changes in the symptom scores of the patients and the FSFI scores were compared. Results: A total of 38 patients completed the study. The mean age of the patients was 41.59±11.79 (31-56), and the mean body mass index was 30.02±4.77 kg/m2. Mean duration of complaints was 48,93±45,32 months and mean number of pads daily used was 3,92±2,39. For the treatment of idiopathic OAB, 100IU Botox application to each patient was performed in 20 regions. Significant improvement was observed in the OABSS scores of the patients 12 weeks after treatment (10.32±3.01 to 4.68±2.21; p<0.001). When the FSFI scores were examined, a significant improvement was observed in the FSFI-desire, arousal, satisfaction, and pain subgroups and total FSFI score 12 weeks after the procedure. In the post-treatment evaluation, 94.73% of the patients were satisfied with the treatment. Urinary retention occurred in two patients. Conclusion: As a result of our study, intravesical botox injections have been shown to improve sexual function in women with OAB. More extensive studies are needed to better evaluate the effects of botox injection on sexual functions.
Keywords: Overactive bladder; botox; female sexual function; urge urinary incontinence
Amaç: Aşırı aktif mesane (AAM) semptomları kadın cinsel fonksiyonu üzerinde olumsuz bir etkiye sahiptir. Bu çalışmanın amacı, AAM'li kadınlarda intravezikal onabotulinumtoksinA (Botoks) enjeksiyonunun kadın cinsel fonksiyonu üzerindeki etkisini araştırmak ve AAM semptomları ile ilişkisini değerlendirmektir. Gereç ve Yöntemler: Ocak 2018-Temmuz 2019 tarihleri arasında idiopatik AAM tanısı olan ve medikal tedaviye dirençli 56 hastanın verileri değerlendirildi. Hastalar 100 IU Botoks tedavisi öncesi ve tedaviden 12 hafta sonra aşırı aktif mesane semptom skoru (OABSS) ve kadın cinsel fonksiyon indeksi [female sexual function index (FSFI)] ile değerlendirildi. Hastaların semptom skorlarındaki değişiklikler ile FSFI skorları arasındaki değişiklikler karşılaştırıldı. Bulgular: Çalışmayı 38 hasta tamamladı. Hastaların yaş ortalaması 41,59±11,79 (31-56), beden kitle indeksi ortalaması 30,02±4,77 idi. Hastaların şikâyet süreleri ortalaması 48,93±45,32 ay, günlük ped kullanımı ortalaması 3,92±2,39'du. İdiopatik AAM tedavisi için her hastaya 100IU Botoks uygulaması 20 bölgeye yapıldı. Tedaviden 12 hafta sonra hastaların OABSS skorlarında anlamlı iyileşme izlendi (10,32±3,01'e 4,68±2,21; p<0,001). FSFI skorları incelendiğinde işlemden 12 hafta sonra FSFI-istek, uyarılma, doyum ve ağrı alt grupları ile toplam FSFI skorunda anlamlı iyileşme olduğu izlendi. Tedavi sonrası değerlendirmede hastaların %94,73'ü tedaviden memnundu. İki hastada idrar retansiyonu gerçekleşti. Sonuç: Çalışmamız sonucunda, intravezikal botoks enjeksiyonlarının AAM'li kadınlarda cinsel fonksiyonu iyileştirebileceği gösterilmiştir. Botoks enjeksiyonunun cinsel fonksiyonlar üzerine etkilerinin daha iyi değerlendirilmesi için konu ile ilgili daha geniş çalışmalara ihtiyaç vardır.
Anahtar Kelimeler: Aşırı aktif mesane; botoks; kadın cinsel fonksiyonu; sıkışma tipi idrar kaçırma
- Zachariou A, Mamoulakis C, Filiponi M, Dimitriadis F, Giannakis J, Skouros S, et al. The effect of mirabegron, used for overactive bladder treatment, on female sexual function: a prospective controlled study. BMC Urol. 2018;18(1):61. [Crossref] [PubMed] [PMC]
- Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010;21(1):5-26. [Crossref] [PubMed]
- Banakhar MA, Al-Shaiji TF, Hassouna MM. Pathophysiology of overactive bladder. Int Urogynecol J. 2012;23(8):975-82. [Crossref] [PubMed]
- Agarwal A, Eryuzlu LN, Cartwright R, Thorlund K, Tammela TL, Guyatt GH, et al. What is the most bothersome lower urinary tract symptom? Individual- and population-level perspectives for both men and women. Eur Urol. 2014;65(6):1211-7. [Crossref] [PubMed] [PMC]
- Sinclair AJ, Ramsay IN. The psychosocial impact of urinary incontinence in women. The Obstetrician & Gynaecologist. 2011;13(3):143-8. [Crossref]
- Andersson KE, Chapple CR, Cardozo L, Cruz F, Hashim H, Michel MC, et al. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol. 2009;19(4):380-94. [Crossref] [PubMed]
- Coyne KS, Sexton CC, Thompson C, Kopp ZS, Milsom I, Kaplan SA. The impact of OAB on sexual health in men and women: results from EpiLUTS. J Sex Med. 2011;8(6):1603-15. [Crossref] [PubMed]
- Gaziev G, Topazio L, Iacovelli V, Asimakopoulos A, Di Santo A, De Nunzio C, et al. Percutaneous Tibial Nerve Stimulation (PTNS) efficacy in the treatment of lower urinary tract dysfunctions: a systematic review. BMC Urol. 2013;13:61. [Crossref] [PubMed] [PMC]
- Musco S, Serati M, Lombardi G, Lumi E, Parisi AI, Del Popolo G, et al. Percutaneous tibial nerve stimulation improves female sexual function in women with overactive bladder syndrome. J Sex Med. 2016;13(2):238-42. [Crossref] [PubMed]
- Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, et al; EMBARK Study Group. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: Results of a phase 3, randomized, placebo controlled trial. J Urol. 2017;197 (2S):S216-S223. [PubMed]
- Homma Y, Yoshida M, Seki N, Yokoyama O, Kakizaki H, Gotoh M, et al. Symptom assessment tool for overactive bladder syndrome--overactive bladder symptom score. Urology. 2006;68(2): 318-23. [Crossref] [PubMed]
- Culha MG, Degirmentepe RB, Ozbir S, Cakir SS, Homma Y. Turkish validation of the overactive bladder symptom score (OABSS) and evaluation of mirabegron treatment response. Int Urogynecol J. 2019;30(12):2121-26. [Crossref] [PubMed]
- Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26(2):191-208. [Crossref] [PubMed]
- Aygin D, Aslan F. The Turkish adaptation of the Female Sexual Function Index [Kadın Cinsel İşlev Ölçeği'nin Türkçeye uyarlaması]. Turkiye Klinikleri Journal of Medical Sciences. 2005;25(3):393-9. [Link]
- Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther. 2005;31(1):1-20. [Crossref] [PubMed]
- Di Marco J, De Broglie C, Manceau P, Weglinski L, Le Breton F, Verrollet D, et al. Les anticholinergiques ne modifient pas la fonction sexuelle chez les patientes atteintes de sclérose en plaques [Anticholinergics do not affect the sexual function in women diagnosed with multiple sclerosis]. Prog Urol. 2016;26(4):226-9. French. [Crossref] [PubMed]
- Dursun P, Dogan NU, Kolusari A, Dogan S, Ugur MG, Komurcu O, et al. Differences in geographical distribution and risk factors for urinary incontinence in Turkey: analysis of 6,473 women. Urol Int. 2014;92(2):209-14. [Crossref] [PubMed]
- Kocak I, Okyay P, Dundar M, Erol H, Beser E. Female urinary incontinence in the west of Turkey: prevalence, risk factors and impact on quality of life. Eur Urol. 2005;48(4):634-41. [Crossref] [PubMed]
- Sarici H, Ozgur BC, Telli O, Doluoglu OG, Eroglu M, Bozkurt S. The prevalence of overactive bladder syndrome and urinary incontinence in a Turkish women population; associated risk factors and effect on Quality of life. Urologia. 2016; 83(2): 93-8. [Crossref] [PubMed]
- Cakir SS, Degirmentepe RB, Atalay HA, Canat HL, Ozbir S, Culha MG, et al. The effect of overactive bladder treatment with anticholinergics on female sexual function in women: a prospective observational study. Int Urol Nephrol. 2019;51(1): 27-32. [Crossref] [PubMed]
- Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013;64(2):249-56. [Crossref] [PubMed]
- Nitti VW, Ginsberg D, Sievert KD, Sussman D, Radomski S, Sand P, et al; 191622-096 Investigators. durable efficacy and safety of long-term onabotulinumtoxina treatment in patients with overactive bladder syndrome: final results of a 3.5-year study. J Urol. 2016;196(3):791-800. [PubMed]
- Miotla P, Cartwright R, Skorupska K, Bogusiewicz M, Markut-Miotla E, Futyma K, et al. Impact of intravesical onabotulinumtoxinA on sexual function in women with OAB. Neurourol Urodyn. 2017; 36(6):1564-9. [Crossref] [PubMed]
- Balzarro M, Rubilotta E, Braga A, Bassi S, Processali T, Artibani W, et al. OnabotulinumtoxinA detrusor injection improves female sexual function in women with overactive bladder wet syndrome. Eur J Obstet Gynecol Reprod Biol. 2018;225:228-31. [Crossref] [PubMed]
.: Process List